Aldosterone Identifies a High-Risk Recurrent Phenotype in Severe Hypertension (NCT07535814) | Clinical Trial Compass
CompletedNot Applicable
Aldosterone Identifies a High-Risk Recurrent Phenotype in Severe Hypertension
Argentina500 participantsStarted 2022-03-01
Plain-language summary
Acute severe hypertension is a common and heterogeneous clinical condition associated with significant short-term morbidity and health care utilization. Despite its frequency, underlying pathophysiological mechanisms remain poorly characterized, particularly regarding the role of aldosterone dysregulation beyond classical primary aldosteronism.
The VATAHTA Acute Study is an observational cohort study designed to evaluate the association between aldosterone levels, renin profiles, and clinical outcomes in patients presenting with acute severe hypertension requiring hospital admission. The study aims to characterize a potential spectrum of aldosterone dysregulation and its relationship with short-term clinical severity, including length of hospital stay, target organ damage, and cardiovascular events.
By integrating clinical, biochemical, and outcome data, this study seeks to improve the understanding of pathophysiological phenotypes in acute severe hypertension and identify potential targets for risk stratification and future therapeutic strategies.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Adults aged ≥18 years Hospital admission due to acute severe hypertension, defined as systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥120 mmHg requiring in-hospital management Availability of plasma aldosterone and renin measurements at hospital admission or within the first 24 hours Availability of key clinical and laboratory data, including blood pressure, renal function, and serum potassium levels
Exclusion Criteria:
Pregnancy or hypertensive disorders of pregnancy Known secondary hypertension due to endocrine causes other than suspected aldosterone dysregulation (e.g., pheochromocytoma, Cushing syndrome) Patients receiving chronic dialysis Severe acute conditions likely to independently determine short-term outcomes (e.g., septic shock, major trauma) Missing key data required for primary outcome assessment (length of hospital stay) Prior inclusion in the study cohort
\-
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Length of hospital stay
Timeframe: rom hospital admission to discharge (index hospitalization), an average of 36 months
Trial details
NCT IDNCT07535814
SponsorSchool of Medicine. National University of Cuyo